Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.034 | 0.7 |
mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.031 | 0.7 |
mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.027 | 0.7 |
mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.037 | 0.7 |
mRNA | spautin-1 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |